
Viking Therapeutics (VKTX) Stock Forecast & Price Target
Viking Therapeutics (VKTX) Analyst Ratings
Bulls say
Viking Therapeutics Inc. demonstrates a robust outlook due to its strategic advancements in biopharmaceutical development, particularly concerning its pipeline, which includes VK2809, VK5211, and VK0214, that target significant metabolic and endocrine disorders. The company has proactively secured large-scale production capacity and manufacturing agreements, enhancing its competitive positioning in the obesity treatment market, which is experiencing substantial growth. Additionally, the promising clinical trial results, including superior weight loss metrics compared to competitors, alongside potential therapeutic area market expansions, bolster the long-term value proposition for the firm.
Bears say
Viking Therapeutics Inc is facing a negative outlook primarily due to an expected increase in research and development expenses, which has led to a downward revision in financial projections. Concerns regarding negative safety or efficacy results from late-stage clinical trials pose significant risks, potentially resulting in further reductions to revenue forecasts and impacting market penetration for its drug candidates. Additionally, disappointing earnings results, including an earnings per share figure that fell below estimates, emphasize ongoing financial challenges and the uncertainties surrounding the progression of Viking's clinical programs.
This aggregate rating is based on analysts' research of Viking Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Viking Therapeutics (VKTX) Analyst Forecast & Price Prediction
Start investing in Viking Therapeutics (VKTX)
Order type
Buy in
Order amount
Est. shares
0 shares